Skip to Content

Recession-Resistant Medicine

Novel medical treatments thrive as investors get cautious.
December 22, 2008

In the third quarter of 2008, the first tremors of the financial crisis had been felt, and the number of venture deals in the U.S. fell to its lowest total since early 2005. According to Dow Jones’s VentureWire, which tracks venture investment, information technology companies fared particularly badly, with their lowest deal total in more than 10 years.

But for the quarter, total dollars invested stayed fairly steady, off only about 1 percent from each of the first two quarters. So some companies were still getting big paydays. Of the 10 companies with the biggest third-quarter deals, the plurality–four–were in the health-care sector. One of those companies, Pacific Biosciences, builds genome-sequencing machines and figures prominently in Emily Singer’s “Interpreting the Genome.” The other three are testing promising new therapies for some of the most common medical conditions.

Head of the Class
Biggest deals, third quarter of 2008

Source: VentureWire

CVRx

Between 25 and 33 percent of hypertension patients can’t control their condition with medication. But the body has its own mechanisms for bringing blood pressure down, which are triggered by nerve cells in the carotid artery that respond to pressure. CVRx has found a way to treat severe, drug-resistant hypertension by stimulating those nerves electrically. A device the size of an iPod Nano is implanted in the patient’s chest, with electrical leads snaking up to the carotid artery. The device is now in phase III clinical trials in the U.S. and Europe.

Product: Arterial stimulation to control hypertension

CEO: Nadim Yared

Location: Minneapolis, MN

Funders: New Enterprise Associates, Johnson and Johnson Development Corporation, others

Funding: $209 million

URL: cvrx.com

Proteolix

Cells clean up unneeded proteins by shipping them to a structure called the proteasome, which chops them up. If the ­proteasome can’t do its job, the cell eventually dies. By targeting a specific component of the structure, Proteolix has developed a proteasome inhibitor that is particularly deadly to cancer cells. In the right doses, it kills cancer with little damage to healthy tissue. A variation on the molecule targets the proteasomes in immune cells (which differ from those in normal cells), disrupting biochemical pathways that cause autoimmune disorders.

Product: Drugs that target the proteasome

CEO: Susan Molineaux

Location: South San Francisco, CA

Funders: Nomura Phase4 Ventures, Advanced Technology Ventures, Delphi Ventures, others

Funding: $143 million

URL: proteolix.com

Portola

Portola’s drugs treat blood clots, which form when ­collagen-containing plaques on artery walls rupture. Collagen is one of the supportive tissues in blood vessels, so the body reads its sudden appearance as indication of a wound, which it sends blood-clotting agents to repair. Portola designed an imaging system that lets researchers observe blood clots forming in collagen-lined capillary tubes. The simulations led to a drug candidate that’s in clinical trials as a competitor to Plavix, the world’s second-best-­selling drug.

Product: Drugs for treating blood clots

CEO: Charles Homcy

Location: South San Francisco, CA

Funders: Advanced Technology Ventures, Prospect Venture Partners, Sutter Hill Ventures, MPM Capital, others

Funding: $218 million

URL: portola.com

Keep Reading

Most Popular

Large language models can do jaw-dropping things. But nobody knows exactly why.

And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.

OpenAI teases an amazing new generative video model called Sora

The firm is sharing Sora with a small group of safety testers but the rest of us will have to wait to learn more.

Google’s Gemini is now in everything. Here’s how you can try it out.

Gmail, Docs, and more will now come with Gemini baked in. But Europeans will have to wait before they can download the app.

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.